The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
暂无分享,去创建一个
J. Holst | C. Cobelli | R. Rizza | G. Toffolo | C. Dalla Man | Francesco Micheletto | A. Vella | R. Basu | C. Deacon | P. Giesler | G. Bock | J. Laugen
[1] Claudio Cobelli,et al. Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes , 2009, Diabetes Care.
[2] F. Toledo,et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.
[3] J. Holst,et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. , 2008, Diabetes care.
[4] T. Hansen,et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study , 2008, Diabetologia.
[5] Michael Camilleri,et al. Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes , 2007, Diabetes.
[6] Claudio Cobelli,et al. Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes , 2007, Diabetes.
[7] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[8] J. Holst,et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.
[9] W. Zeng,et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses , 2005, Clinical pharmacology and therapeutics.
[10] D. Pereg,et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. , 2005, The New England journal of medicine.
[11] M. Hanefeld,et al. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. , 2005, Metabolism: clinical and experimental.
[12] Claudio Cobelli,et al. Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. , 2005, American journal of physiology. Endocrinology and metabolism.
[13] A. Tura,et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. , 2004, Metabolism: clinical and experimental.
[14] J. Holst,et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.
[15] T. Hughes,et al. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.
[16] J. Holst,et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.
[17] C Cobelli,et al. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. , 2001, Diabetes.
[18] Claudio Cobelli,et al. Oral Glucose Tolerance Test Minimal Model Indexes of β-Cell Function and Insulin Sensitivity , 2001 .
[19] M. Stumvoll,et al. Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion , 2000, Diabetologia.
[20] C. Bogardus,et al. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. , 1999, Diabetes.
[21] J. Holst,et al. Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.
[22] M. Beylot,et al. Determination of the 13C-labeling pattern of glucose by gas chromatography-mass spectrometry. , 1993, Analytical biochemistry.
[23] Jeppe Sturis,et al. Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance , 1992, Diabetes.
[24] R. Steele,et al. Glucose Uptake and Production During the Oral Glucose Tolerance Test , 1968, Diabetes.